Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0015674 (chronic fatigue syndrome)
 2,978 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In vitro activity of antimicrobial agents such as ABPC, SBPC, MPC, CEZ, CTM, CMZ, CTX, CMX, CZX, LMOX, CPZ, CFS and GM against major clinical isolates, S. aureus, S. pyogenes, E. coli, K. pneumoniae, P. mirabilis, C. freundii, Enterobacter spp., S. marcescens, P. vulgaris and P. aeruginosa, was examined. In this paper, we will report the susceptibility of S. aureus, S. pyogenes, E. coli, K. pneumoniae and P. mirabilis during a three-year period, 1981 to approximately 1983. CEZ- and GM-resistant S. aureus has markedly increased and occupied 24% and 18%, respectively, in 1983. CMZ and CFS have showed potent activity against CEZ-resistant S. aureus. It seems that the abuse of third generation-cephems and new oral cephalosporins is closely related with the increase of cephems-resistant S. aureus. The penicillin- and cephem-resistant strains of S. pyogenes could not be found in our study. Quite a few strains of E. coli, K. pneumoniae and P. mirabilis are resistant to penicillins, and also there is no appreciable change in susceptibility. Some strains of E. coli, K. pneumoniae and P. mirabilis showed low susceptibility to CPZ, but all strains showed high susceptibility and no change in susceptibility to third generations, and these strains showed no tendency to decrease in susceptibility to GM.
 ...
PMID:[Distribution and changes in the susceptibility of bacteria isolated from clinical samples. II]. 390 Apr 59

Fundamental and clinical studies were carried out on ceftazidime ( CAZ ), a new cephalosporin, in the field of pediatrics. 1. Antimicrobial activity MICs of CAZ were determined for clinical isolates of 24 strains of S. aureus, 15 of S. pyogenes, 8 of H. influenzae, 22 of E. coli, 20 of K. pneumoniae, 18 of P. mirabilis, 3 of P. morganii, and 21 of P. aeruginosa, and compared with those of the control drugs, i.e. CEZ, CXM, CMZ, CTX, LMOX and CMX. For P. aeruginosa, CPM, CFS and GM were also employed as the control drugs. CAZ was as active as CTX, LMOX and CMX, its MICs distributing in the range not higher than 0.10 microgram/ml for H. influenzae, 0.78 microgram/ml for E. coli, 0.39 microgram/ml for K. pneumoniae, 0.10 microgram/ml for P. mirabilis, and 0.10 microgram/ml for P. morganii in all the strains. Against P. aeruginosa, CAZ showed MICs in the range between 0.39 and 3.13 micrograms /ml, which showed activity higher than that of CTX, LMOX , CPM, CMX and GM, and comparable to that of CFS. Against S. pyogenes, CAZ was as active as all the control drugs except for LMOX , its MICs for all strains tested being 0.20 microgram/ml or below. Against S. aureus, CAZ was slightly more active than LMOX , but less active than the other control drugs, its MICs being relatively high ranging from 6.25 to 50 micrograms/ml. 2. Pharmacokinetics After a one-shot intravenous injection of CAZ 20 mg/kg, serum levels and urinary excretion were studied in 3 children aged 6 to 9 years, and CSF levels were determined in 2 children aged 6 to 7 years with aseptic meningitis. The mean serum levels of CAZ were 85.3 micrograms/ml at 1/4 hour, 53.3 micrograms/ml at 1/2 hour, 32.0 micrograms/ml at 1 hour, 16.1 micrograms/ml at 2 hours, 5.3 micrograms/ml at 4 hours, and 2.0 micrograms/ml at 6 hours, with the mean half-life of 1.18 hours. The mean urinary levels were 9,700 micrograms/ml at 0 to 2 hours, 803 micrograms/ml at 2 to 4 hours, 540 micrograms at 4 to 6 hours, and the mean urinary recovery rate during the first 6 hours was 83.9%. The CSF levels at 1 hour after intravenous injection were 0.44 microgram/ml in acute stage and 0.10 to 0.22 microgram/ml in convalescent stage. 3. Clinical study Thirty-one pediatric patients with bacterial infections were treated with CAZ , and the clinical efficacy, bacteriological response, and side effects were evaluated.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:[Fundamental and clinical studies on ceftazidime in the field of pediatrics]. 637 58

In vitro activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections were investigated by dilution method using MIC 2000 (Dynatec) during July to October in 1982. The summarized results are as follows: PMPC and CCL have showed potent activities against E coli among the oral antimicrobial agents. PMPC and CCL at 3.13 micrograms/ml inhibited 90% of E. coli tested. CTM, CTX, CZX, CMX and LMOX at concentrations of 0.39 microgram/ml or less among the parenteral antimicrobial agents inhibited 90% of E. coli tested. The value of MIC90 (concentration at which 90% of isolates are inhibited) against K. pneumoniae results in the resistant range for ABPC, NA, CEX, CCL and ST. Among the parenteral cephems, CMX seemed most effective against K. pneumoniae tested. C. freundii seemed generally low susceptible to antimicrobial agents tested. Among the oral agents, PMPC, PPA and ST have showed moderate activity against C. freundii. Among the parenteral agents, CMX and LMOX also showed moderate activity against C. freundii, inhibiting 50% of the strains tested at 6.25 micrograms/ml. Among the oral agents, PMPC showed the most potent activity against E. cloacae. E. cloacae tested were highly resistant to the first and second generation cephems. Among the third generation, CMX seemed the most potent activity against E. cloacae isolated. However, CMX concentration of 1.56 micrograms/ml was necessary to inhibit 50% of tested E. cloacae. P. mirabilis tested was resistant to all oral antimicrobial agents except CCL and ST. The value of MIC90 of the first and second generation cephems against P. mirabilis results in the moderately susceptible range (6.25-25 micrograms/ml). The third generation seemed most effective against P. mirabilis tested. PMPC, NA, PPA and ST concentrations of 0.78-1.56 micrograms/ml were necessary to inhibit 50% of tested P. vulgaris. CEZ and CTM, seemed less potent activity than CFX and CMZ against P. vulgaris. CTX, CZX, CMX and LMOX except CPZ have showed potent activities against P. vulgaris, these at 0.1 micrograms/ml or less inhibited 50% of P. vulgaris tested. P. aeruginosa has been resistant to the third generation cephems except CPZ, but TOB, GM, AMK, CFS, PIPC and CPZ have showed high activities against P. aeruginosa, inhibiting 50% of the strains tested at 0.39-6.25 micrograms/ml. The oral antimicrobial agents, and first and second generation cephems had not showed significant activity against S. marcescens. And strains of S. marcescens were relatively susceptible to the third generation cephems.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:[Comparative studies of antimicrobial agents against causative organisms isolated from urinary tract infections (1982). I. Susceptibility distribution]. 643 64

Fundamental and clinical studies on cefpiramide (CPM), a new semisynthetic cephalosporin were performed and the following results were obtained. Antibacterial activity The antibacterial activity of CPM was investigated in comparison with those of CTT, CPZ, CEZ, LMOX and CFS. Against clinical isolates of S. aureus, CPM was superior to CTT and LMOX, but almost similar to CPZ and inferior to CEZ. Against E. coli, K. pneumoniae, P. mirabilis and S. marcescens, CPM showed the activity almost similar to that of CEZ, but inferior to those of the others. On the contrary, the activity of CPM against P. aeruginosa was satisfactory and was superior to those of CTT, CPZ and LMOX, but slightly inferior to that of CFS. Blood level and urinary recovery Twenty mg/kg of CPM was given intravenously at one shot to 3 patients. The mean serum levels of CPM were 116.9 micrograms/ml at 30 minutes, 90.5 micrograms/ml at 1 hour, 71.1 micrograms/ml at 2 hours, 55.8 micrograms/ml at 4 hours, 24.9 micrograms/ml at 6 hours, 19.3 micrograms/ml at 9 hours and 12.1 micrograms/ml at 12 hours after administration, respectively. The mean half-life was very long and the value was 3.85 hours. The urinary recovery rates in 2 cases were 18.31 and 21.47% respectively up to 12 hours after administration. Clinical results and side effects CPM was given intravenously to 30 diseases including 11 cases of bronchopneumonia, 3 cases of bronchopneumonia and pleurisy, 2 cases of bronchitis, 4 cases of purulent tonsillitis, 5 cases of pyelonephritis and each one case of pyothorax, parotitis, cellulitis, otitis media and salmonellosis. CPM was effective in 29 out of 30 cases, and the effective rate was 96.7%. As side effects, 2 cases of fever and 1 case of cough were observed, but no abnormality in clinical laboratory findings was observed.
 ...
PMID:[Experimental and clinical evaluation of cefpiramide in pediatrics]. 665 42